Clearstead Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Clearstead Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$370	Buy	+55	New	+$434	﹤0.01%	3020
2025 Q2	–	Sell	-60	Closed	-$636	–	2739
2025 Q1	$636	Hold	60	–	–	﹤0.01%	2043
2024 Q4	$1.02K	Buy	60 +40	+200%	+$753	﹤0.01%	1916
2024 Q3	$465	Hold	20	–	–	﹤0.01%	1957
2024 Q2	$487	Hold	20	–	–	﹤0.01%	1939
2024 Q1	$575	Hold	20	–	–	﹤0.01%	1445
2023 Q4	$631	Hold	20	–	–	﹤0.01%	1443
2023 Q3	$511	Hold	20	–	–	﹤0.01%	1415
2023 Q2	$574	Hold	20	–	–	﹤0.01%	1291
2023 Q1	$480	Hold	20	–	–	﹤0.01%	1306
2022 Q4	$339	Hold	20	–	–	﹤0.01%	1256
2022 Q3	$0	Hold	20	–	–	﹤0.01%	1243
2022 Q2	$0	Hold	20	–	–	﹤0.01%	1273
2022 Q1	$1K	Hold	20	–	–	﹤0.01%	1263
2021 Q4	$1K	Hold	20	–	–	﹤0.01%	1155
2021 Q3	$1K	Hold	20	–	–	﹤0.01%	1178
2021 Q2	$1K	Buy	+20	New	+$677	﹤0.01%	1121

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Clearstead Advisors's ARCT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Arcturus Therapeutics (ARCT) in Q2 2026: 55 shares worth $370. The stake represents ﹤0.01% of the portfolio and ranks #3020 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ARCT as recently as Q1 2025.

Clearstead Advisors first reported a position in ARCT in Q2 2021 and has held it in 17 quarters since. The position peaked at $1.02K in Q4 2024. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Clearstead Advisors held 55 shares of Arcturus Therapeutics worth $370 as of Q2 2026.
Arcturus Therapeutics was a new Clearstead Advisors position in Q2 2026.
Arcturus Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3020 holding.
Clearstead Advisors first reported a position in Arcturus Therapeutics in Q2 2021 and has held it in 17 quarters since.
Clearstead Advisors's Arcturus Therapeutics position peaked at $1.02K in Q4 2024.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.